BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Isomorphic Labs Raises $600M to Advance AI Drug Design and Internal Pipeline

by BiopharmaTrend   •   March 31, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Startups & Deals   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Isomorphic Labs has secured $600 million in its first external funding round to accelerate the development of its AI-based drug design engine and support the advancement of internal therapeutic programs into the clinic. The round was led by Thrive Capital, with participation from GV and follow-on investment from Alphabet, the company’s founding backer.

#advertisement
AI in Drug Discovery Report 2025

Founded in 2021 by Sir Demis Hassabis by Demis Hassabis as a London-based spin-off from Alphabet’s DeepMind, Isomorphic Labs focuses on integrating frontier AI research with drug discovery. The company has built a suite of AI models that together form a unified drug design engine capable of operating across multiple therapeutic areas and drug modalities. Among its key technical milestones is AlphaFold 3—developed in collaboration with Google DeepMind—which was released in May 2024 and is designed to predict the structure and interactions of biological molecules with high accuracy.

According to the company, the newly raised capital will fund further AI model innovation, expand its internal R&D programs—primarily in oncology and immunology—and support growth of its London and Lausanne-based team. In addition to its proprietary pipeline, Isomorphic Labs has established partnerships with pharmaceutical companies including Eli Lilly and Novartis, with the latter recently expanding the scope of its collaboration.

The company stated that the funding will enable continued scaling of its computational platform and support the long-term goal of developing AI-driven methods for discovering and designing new treatments across disease areas.

Cover image: Googe DeepMind

Topics: Startups & Deals   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.